1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Satoh, F.; Okado, T.; Iwamoto, M.; Akita, W.; Wakabayashi, M.; Ohta, A.; Sohara, E.; Noda, Y.; Rai, T.; Uchida, S.; et al.
Calcium-alkali syndrome-like symptoms manifested by daily alphacalcidol and thiazide. Intern. Med. 2010, 49, 837–840.
[CrossRef]
Kleinig, T.J.; Torpy, D.J. Milk-alkali syndrome: Broadening the spectrum of causes to allow early recognition. Intern. Med. J. 2004,
34, 366–367. [CrossRef] [PubMed]
Hanada, S.; Iwamoto, M.; Kobayashi, N.; Ando, R.; Sasaki, S. Calcium-alkali syndrome due to vitamin D administration and
magnesium oxide administration. Am. J. Kidney Dis. 2009, 53, 711–714. [CrossRef]
Palmer, B.F.; Clegg, D.J. The use of selected urine chemistries in the diagnosis of kidney disorders. Clin. J. Am. Soc. Nephrol. 2019,
14, 306–316. [CrossRef] [PubMed]
Khow, K.S.; Lau, S.Y.; Li, J.Y.; Yong, T.Y. Diuretic-associated electrolyte disorders in the elderly: Risk factors, impact, management
and prevention. Curr. Drug Saf. 2014, 9, 2–15. [CrossRef] [PubMed]
Lamberg, B.A.; Kuhlback, B. Effect of chlorothiazide and hydrochlorothiazide on the excretion of calcium in urine. Scand. J. Clin.
Lab. Investig. 1959, 11, 351–357. [CrossRef]
Parfitt, A.M. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyrxoidism. N. Engl. J. Med. 1969,
281, 55–59. [CrossRef]
Paillard, M.; Bichara, M. Peptide hormone effects on urinary acidification and acid-base balance: PTH, ADH, and glucagon. Am.
J. Physiol. 1989, 256, F973–F985. [CrossRef]
Girardi, A.C.; Titan, S.M.; Malnic, G.; Reboucas, N.A. Chronic effect of parathyroid hormone on NHE3 expression in rat renal
proximal tubules. Kidney Int. 2000, 58, 1621–1631. [CrossRef]
Sutton, R.A.; Wong, N.L.; Dirks, J.H. Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog
kidney. Kidney Int. 1979, 15, 520–533. [CrossRef]
Peraino, R.A.; Suki, W.N. Urine HCO3 − augments renal Ca2+ absorption independent of systemic acid-base changes. Am. J.
Physiol. 1980, 238, F394–F398. [CrossRef] [PubMed]
Punsar, S.; Somer, T. The milk-alkali syndrome. A report of three illustrative cases and a review of the literature. Acta Med. Scand.
1963, 173, 435–449. [CrossRef] [PubMed]
Böhmig, G.A.; Schmaldienst, S.; Hörl, W.H.; Mayer, G. Iatrogenic hypercalcaemia, hypokalaemia and metabolic alkalosis in a lady
with vena cava thrombosis—Beware of overzealous diuretic treatment. Nephrol. Dial. Transplant. 1999, 14, 782–784. [CrossRef]
[PubMed]
Jeong, J.H.; Bae, E.H. Hypercalcemia associated with acute kidney injury and metabolic alkalosis. Electrolyte Blood Press. 2010, 8,
92–94. [CrossRef]
Homler, H. Use of furosemide for milk-alkali syndrome. Mayo Clin. Proc. 2009, 84, 562. [CrossRef]
Picolos, M.K.; Lavis, V.R.; Orlander, P.R. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal
disease (non-ESRD) inpatients. Clin. Endocrinol. 2005, 63, 566–576. [CrossRef]
Vassallo, P.; Green, N.; Courtney, E. Hypercalcemia secondary to excessive self-medication with antacids causing acute pancreatitis:
A case report. Croat. Med. J. 2019, 60, 42–45. [CrossRef]
Parvataneni, S.; Essrani, R.; Mehershahi, S.; Essrani, R.; Lohana, A.K.; Mehmood, A. Over-the-counter drug causing acute
pancreatitis. J. Investig. Med. High Impact Case Rep. 2020, 8, 2324709620922724. [CrossRef]
Vu, K.; Becker, G.; Eagerton, D. A 39-year-old woman with milk-alkali syndrome complicated by posterior reversible encephalopathy syndrome. Bone Rep. 2020, 12, 100278. [CrossRef]
The 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS beers
Criteria® for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2019, 67, 674–694. [CrossRef]
O’Mahony, D.; O’Sullivan, D.; Byrne, S.; O’Connor, M.N.; Ryan, C.; Gallagher, P. STOPP/START Criteria for Potentially
Inappropriate Prescribing in Older People: Version 2. Age Ageing 2015, 44, 213–218. [CrossRef]
Hamano, J.; Tokuda, Y. Risk factors and specific prescriptions related to inappropriate prescribing among Japanese elderly home
care patients. Gen. Med. 2014, 15, 117–125. [CrossRef]
Bories, M.; Bouzillé, G.; Cuggia, M.; Le Corre, P. Drug-drug interactions in elderly patients with potentially inappropriate
medications in primary care, nursing home and hospital settings: A systematic review and a preliminary study. Pharmaceutics
2021, 13, 266. [CrossRef] [PubMed]
Fushiki, Y.; Kinoshita, K.; Tokuda, Y. Polypharmacy and adverse drug events leading to acute care hospitalization in Japanese
elderly. Gen. Med. 2014, 15, 110–116. [CrossRef]
Medicina 2023, 59, 1345
25.
26.
8 of 8
Mangin, D.; Bahat, G.; Golomb, B.A.; Mallery, L.H.; Moorhouse, P.; Onder, G.; Petrovic, M.; Garfinkel, D. International Group for
Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position statement and 10 recommendations for action.
Drugs Aging 2018, 35, 575–587. [CrossRef] [PubMed]
Bloomfield, H.E.; Greer, N.; Linsky, A.M.; Bolduc, J.; Naidl, T.; Vardeny, O.; MacDonald, R.; McKenzie, L.; Wilt, T.J. Deprescribing
for community-dwelling older adults: A systematic review and meta-analysis. J. Gen. Intern. Med. 2020, 35, 3323–3332. [CrossRef]
[PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.
...
論文の公開元へ
